🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

No todo lo que parece lógico en medicina… funciona en la práctica. 🩸 Validar intervenciones médicas exige más que intuición: requiere ciencia. Por eso los ensayos clínicos aleatorizados siguen siendo el estándar más robusto para evaluar eficacia y seguridad. Desde el diseño

3 cervezas y uno Abstract. Best way of wrapping the day in Lugano! Dont miss it! Glad to have the company of my great friends Laura Korin and Joaquín Díaz-Schmidt!

How we translate a genomic classification into treatment! #ICML2025 #18ICML

Q and A in #18ICML follicular lymphoma session as an example of how to critically appraise trials. R-ibrutinib vs R-placebo in unfit pts with gelf criteria. Table 1 not showing clear evidence that these pts are truly unfit for r-cvp and a weak control arm when r2 is a possibility

Tafa-R-len improved PFS and TTNT in R/R FL without loss of cd19 expression at relapse (important for those who have cart therapy as a treatment possibility in 3L and beyond) #18ICML #ICML2025

Directamente desde ICML-18 en Lugano, Suiza, debuta el segmento: “Tres cervezas y un abstract”, esta vez discutiendo los resultados del ensayo “POLARGO” y la muerte del R-GemOx. Se recomienda acompañar de una cerveza helada. Laura Korin Guilherme Perini, MD Joaquín Díaz-Schmidt #ICML18

Queria aprovechar para contarles q fue en el ICML-17 donde surgió esta idea de fase 3. Felices 2 años de planear, discutir trabajos y divertirnos a mis 2 coanfitriones y amigos! Joaquín Díaz-Schmidt Guilherme Perini, MD

Is Acala-benda-R the new soc for transplant ineligible high risk patients in mantle cell lymphoma? Thoughts? #18ICML #ICML2025

Together we lead, we learn, we lift each other up. Thank you to all who joined our WiL gathering at #18ICML — an inspiring evening filled with connection, purpose, and power. Let’s keep building this global community, one voice at a time. 🌍 #womeninhematology #ICML2025

The new debate in advanced stage HL treatment. #18ICML #ICML2025

Lots of "chemo free" or "chemo light" trials for elderly patients. Not exempt of toxicity (adverse events and time). Not convinced that this is better than R-mini-chop. #18ICML #ICML2025

Problem: these classification tools are not accessible to vast majority of oncologists (particularly in the community where majority of DLBCL is treated). Very challenging to say from the podium that we should be doing this in routine clinical practice. #lymsm #18ICML 1/

The benefit of pola R chp seems to be limited to C5. How does it compare to the data of the Phoenix trial and the benefit in MCD subgroup? #18ICML #ICML2025

SUNMO trial. It is funny how geographical subgroups have become "a thing" after starglo. #18ICML #ICML2025

How to interpret p-values 😅

Top Oncologists from 18th International Conference on Malignant Lymphoma (International Conference on Malignant Lymphoma 2025). Explore data and insights #ICML2025: t.ly/dz8T1 #LARVOL #Hematology #Lymphoma #CancerResearch #Oncology #CancerData #OncologyInsights #18ICML | Graham Collins | Ajay Major, MD, MBA |

Board review after party in Sao Paulo with great friends! Thanks for the invitation Guilherme Perini, MD and Fabio Pires and see you all soon!

📣join our educational webinar tomorrow @ 3pm EST PATHOGENS AND LYMPHOMA - Microbiome in lymphomas with Catherine Diefenbach, Paola Ghione MD, MSEpi, Florence Broussais-Guillaumot and Soni Smith MD Register ➡️ us06web.zoom.us/webinar/regist…

Critical appraisal is a tool, not a weapon!

Don't miss this week's WILing wednesday! Dr Thieblemont and Dr Arai answering one of the questions frequently asked in the clinic: do infectious agents drive lymphoma initiation? Link below